TSW
CHRS icon

Thompson Siegel & Walmsley’s Coherus Oncology CHRS Stock Holding History

Thompson Siegel & Walmsley’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,070
Closed -$97K – 559
2022
Q3 		$97K Buy
10,070
+854
+9% +$8.64K ﹤0.01% 390
2022
Q2 		$67K Sell
9,216
-696,440
-99% -$6.06M ﹤0.01% 400
2022
Q1 		$9.11M Buy
705,656
+147,193
+26% +$1.87M 0.13% 163
2021
Q4 		$8.91M Sell
558,463
-43,908
-7% -$768K 0.12% 160
2021
Q3 		$9.68M Sell
602,371
-207,042
-26% -$3.03M 0.14% 148
2021
Q2 		$11.2M Buy
809,413
+144,850
+22% +$2.05M 0.15% 131
2021
Q1 		$9.71M Buy
664,563
+152,710
+30% +$2.59M 0.14% 138
2020
Q4 		$8.9M Buy
511,853
+137,168
+37% +$2.44M 0.14% 140
2020
Q3 		$6.87M Sell
374,685
-58,532
-14% -$1.09M 0.13% 142
2020
Q2 		$7.74M Buy
+433,217
New +$7.33M 0.16% 127

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Thompson Siegel & Walmsley's CHRS Position: Q4 2022 in Review

Thompson Siegel & Walmsley sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 10,070 shares — an estimated $97K sold.

Thompson Siegel & Walmsley first reported a position in CHRS in Q2 2020 and held it in 10 quarters. The position peaked at $11.2M in Q2 2021. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

  • Thompson Siegel & Walmsley reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 10,070 Coherus Oncology shares in Q4 2022, an estimated $97K.
  • Thompson Siegel & Walmsley first reported a position in Coherus Oncology in Q2 2020 and held it in 10 quarters.
  • Thompson Siegel & Walmsley's Coherus Oncology position peaked at $11.2M in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2022, filed 10 Feb 2023.